Orly Weinstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Orly Weinstein has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Abdulla Watad
Department of Internal Medicine B, Sheba Medical Center, Tel-Hashomer, Ramat Gan 5262100, Israel
1 shared publication - Alina Rosenberg
Israel Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan 5262100, Israel
1 shared publication - Amy R. Sharn
Global Medical Affairs and Research, Abbott Nutrition, Columbus, OH 43219, USA
1 shared publication - Basel Ahmaro
Department of Internal Medicine B, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel
1 shared publication - Ehud Davidson
United Hatzalah, Jerusalem 36233, Israel
1 shared publication - Gil Lavie
Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel
1 shared publication
Latest Publications
- Open Access
Nutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk
Background/Objectives: Malnutrition in hospitalized older adults is associated with increased healthcare utilization, prolonged hospitalizations, and higher readmission rates. Specialized oral nutritional supplements enriched with β-hydroxy-β-methylbutyrate (HMB-ONS) have shown benefits in preserving muscle mass, improving functional outcomes, and reducing readmission rates, yet real-world data on their effectiveness remain limited. This study evaluated the association between HMB-ONS use and hospital readmission rates, as well as healthcare costs, in patients with malnutrition or at risk of malnutrition. Methods: This retrospective study analyzed electronic medical records (2015–2021) of hospitalized patients at risk of malnutrition at two tertiary care hospitals in Israel. Patients receiving HMB-ONS during hospitalization were compared with those receiving standard ONS (S-ONS). Propensity score matching (PSM) was employed to reduce potential confounding due to differences in observable characteristics. Primary outcomes were readmission rates at 1-, 3-, and 6-month post-discharge. A cost analysis estimated per-patient hospitalization costs and financial savings from reduced readmissions. Results: Of 391,838 hospitalizations, 16,751 patients met the inclusion criteria. Patients with malnutrition or at risk of malnutrition who received HMB-ONS during hospitalization were PSM-matched to those who received S-ONS (n = 1440, 53.5% female, average age of 78.25 (±15.62) years). Patients who received HMB-ONS had significantly lower odds of readmission compared with those receiving S-ONS at 1 month (OR = 0.698; 95% CI: 0.548–0.888; p = 0.0034), 3 months (OR = 0.772; 95% CI: 0.623–0.958; p = 0.0187), and 6 months (OR = 0.780; 95% CI: 0.633–0.961; p = 0.0195). Based on these differences, the economic analysis estimated net cost savings of EUR 387.61 (USD 403.29) per patient for HMB-ONS versus S-ONS. Conclusions: HMB-ONS was associated with significantly lower readmission rates and healthcare costs compared to S-ONS in patients with malnutrition or at risk of malnutrition. These findings may support the use of specialized nutritional interventions to improve clinical outcomes and optimize hospital resource utilization in patients with malnutrition or at risk of malnutrition.
Open AccessNutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk
Background/Objectives: Malnutrition in hospitalized older adults is associated with increased healthcare utilization, prolonged hospitalizations, and higher readmission rates. Specialized oral nutritional supplements enriched with β-hydroxy-β-methylbutyrate (HMB-ONS) have shown benefits in preserving muscle mass, improving functional outcomes, and reducing readmission rates, yet real-world data on their effectiveness remain limited. This study evaluated the association between HMB-ONS use and hospital readmission rates, as well as healthcare costs, in patients with malnutrition or at risk of malnutrition. Methods: This retrospective study analyzed electronic medical records (2015–2021) of hospitalized patients at risk of malnutrition at two tertiary care hospitals in Israel. Patients receiving HMB-ONS during hospitalization were compared with those receiving standard ONS (S-ONS). Propensity score matching (PSM) was employed to reduce potential confounding due to differences in observable characteristics. Primary outcomes were readmission rates at 1-, 3-, and 6-month post-discharge. A cost analysis estimated per-patient hospitalization costs and financial savings from reduced readmissions. Results: Of 391,838 hospitalizations, 16,751 patients met the inclusion criteria. Patients with malnutrition or at risk of malnutrition who received HMB-ONS during hospitalization were PSM-matched to those who received S-ONS (n = 1440, 53.5% female, average age of 78.25 (±15.62) years). Patients who received HMB-ONS had significantly lower odds of readmission compared with those receiving S-ONS at 1 month (OR = 0.698; 95% CI: 0.548–0.888; p = 0.0034), 3 months (OR = 0.772; 95% CI: 0.623–0.958; p = 0.0187), and 6 months (OR = 0.780; 95% CI: 0.633–0.961; p = 0.0195). Based on these differences, the economic analysis estimated net cost savings of EUR 387.61 (USD 403.29) per patient for HMB-ONS versus S-ONS. Conclusions: HMB-ONS was associated with significantly lower readmission rates and healthcare costs compared to S-ONS in patients with malnutrition or at risk of malnutrition. These findings may support the use of specialized nutritional interventions to improve clinical outcomes and optimize hospital resource utilization in patients with malnutrition or at risk of malnutrition.
- Open Access
Elevated Mortality Risk in the First Year Post-Diagnosis of Sarcoidosis: A Comprehensive Population-Based Cohort Study
Background and Objectives: Sarcoidosis, marked by chronic inflammation and granuloma formation, shows a variable clinical course. While many patients have benign outcomes, others face chronic, life-threatening complications. Mortality studies in sarcoidosis show mixed results due to age, ethnicity, sex, and geography, highlighting the need for a comprehensive mortality risk analysis. This study compares mortality risks between sarcoidosis patients and controls, considering demographic and clinical factors, and performs subgroup analyses across different age groups and post-diagnosis periods. Materials and Methods: This is a retrospective cohort study that used Clalit Health Services’ electronic database, including patients first diagnosed with sarcoidosis from 2000 to 2016 and age- and sex-matched controls at a 1:5 ratio. Hazard ratios (HR) for all-cause mortality were obtained using the Cox proportional hazard model, adjusted for sociodemographic and clinical variables. Results: Sarcoidosis patients showed higher mortality rates (17.7%) than controls (10.6%), with an adjusted HR of 1.79 (95% CI: 1.64–1.96, p < 0.001). Subgroup analysis revealed the HR for mortality decreased with age: HR for patients under 50 was 3.04 (95% CI: 2.20–4.21), and for those over 70, it was 1.8 (95% CI: 1.69–2.11). The HR was highest in the first year post-diagnosis. Key mortality predictors included age at diagnosis, male gender, and higher Charlson comorbidity index score. Conclusions: Sarcoidosis patients, particularly younger ones and those with higher comorbidity burdens, have elevated mortality risks compared to controls, with the highest HR in the first year post-diagnosis. These findings highlight the most vulnerable period of the disease.
Open AccessElevated Mortality Risk in the First Year Post-Diagnosis of Sarcoidosis: A Comprehensive Population-Based Cohort Study
Background and Objectives: Sarcoidosis, marked by chronic inflammation and granuloma formation, shows a variable clinical course. While many patients have benign outcomes, others face chronic, life-threatening complications. Mortality studies in sarcoidosis show mixed results due to age, ethnicity, sex, and geography, highlighting the need for a comprehensive mortality risk analysis. This study compares mortality risks between sarcoidosis patients and controls, considering demographic and clinical factors, and performs subgroup analyses across different age groups and post-diagnosis periods. Materials and Methods: This is a retrospective cohort study that used Clalit Health Services’ electronic database, including patients first diagnosed with sarcoidosis from 2000 to 2016 and age- and sex-matched controls at a 1:5 ratio. Hazard ratios (HR) for all-cause mortality were obtained using the Cox proportional hazard model, adjusted for sociodemographic and clinical variables. Results: Sarcoidosis patients showed higher mortality rates (17.7%) than controls (10.6%), with an adjusted HR of 1.79 (95% CI: 1.64–1.96, p < 0.001). Subgroup analysis revealed the HR for mortality decreased with age: HR for patients under 50 was 3.04 (95% CI: 2.20–4.21), and for those over 70, it was 1.8 (95% CI: 1.69–2.11). The HR was highest in the first year post-diagnosis. Key mortality predictors included age at diagnosis, male gender, and higher Charlson comorbidity index score. Conclusions: Sarcoidosis patients, particularly younger ones and those with higher comorbidity burdens, have elevated mortality risks compared to controls, with the highest HR in the first year post-diagnosis. These findings highlight the most vulnerable period of the disease.
- Open Access
- 30 November 2021
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 10 (1) , 1-13
Adapting to change: Clalit's response to the COVID-19 pandemic
The COVID-19 pandemic is the most significant global health event of the past century. The profound and unexpected changes that it brought about have forced healthcare organizations to make far-reaching adjustments to accommodate the new reality. With the outbreak of the pandemic in Israel and the understanding of its consequences, Clalit Health Services (Clalit), the largest healthcare organization in Israel, rapidly mobilized in order to provide the best response possible from the perspective of both its patients and its employees. In the short term, four designated workgroups were established just days into the pandemic. Their task was to prepare operational work plans to achieve the following goals: providing the best possible treatment for COVID patients; maintaining the level of care for non-COVID patients; protecting healthcare personnel without compromising their competence and level of functioning; and beginning the process of post-crisis planning. In the context of the long term, and with the understanding that the changes in healthcare brought about by the COVID-19 pandemic would be long-lasting and irreversible, and would act as a catalyst in Clalit’s preparations for the future, Clalit has carried out the called-for modifications in its organizational strategy. This was based on the need to shift service and treatment foci from the hospitals to the community and the patient’s home and his cellular device, by means of strengthening Clalit’s strategic abilities to become more proactive, more digital and more home-based. In this article, we present a survey of Clalit’s preparations for the new reality in the short and medium terms, as well as the leveraging of insights gained during the first wave of the pandemic, with goal of revising Clalit’s long-term strategic plan. We conclude and point out the organizational abilities required for optimal response to future large-scale emergencies: The ability to quickly identify the need for change, respond quickly while harnessing the various parts of the organization in order to provide an agile and adaptive response, and facilitate long-term planning activity in parallel to providing an operational response in the short and medium terms.
- 30 November 2021
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 10 (1) , 1-13
Open AccessAdapting to change: Clalit's response to the COVID-19 pandemic
The COVID-19 pandemic is the most significant global health event of the past century. The profound and unexpected changes that it brought about have forced healthcare organizations to make far-reaching adjustments to accommodate the new reality. With the outbreak of the pandemic in Israel and the understanding of its consequences, Clalit Health Services (Clalit), the largest healthcare organization in Israel, rapidly mobilized in order to provide the best response possible from the perspective of both its patients and its employees. In the short term, four designated workgroups were established just days into the pandemic. Their task was to prepare operational work plans to achieve the following goals: providing the best possible treatment for COVID patients; maintaining the level of care for non-COVID patients; protecting healthcare personnel without compromising their competence and level of functioning; and beginning the process of post-crisis planning. In the context of the long term, and with the understanding that the changes in healthcare brought about by the COVID-19 pandemic would be long-lasting and irreversible, and would act as a catalyst in Clalit’s preparations for the future, Clalit has carried out the called-for modifications in its organizational strategy. This was based on the need to shift service and treatment foci from the hospitals to the community and the patient’s home and his cellular device, by means of strengthening Clalit’s strategic abilities to become more proactive, more digital and more home-based. In this article, we present a survey of Clalit’s preparations for the new reality in the short and medium terms, as well as the leveraging of insights gained during the first wave of the pandemic, with goal of revising Clalit’s long-term strategic plan. We conclude and point out the organizational abilities required for optimal response to future large-scale emergencies: The ability to quickly identify the need for change, respond quickly while harnessing the various parts of the organization in order to provide an agile and adaptive response, and facilitate long-term planning activity in parallel to providing an operational response in the short and medium terms.